Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized multicenter clinical trial Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Alkylating
  • Dacarbazine
  • Dioxoles
  • Leiomyosarcoma
  • Liposarcoma
  • Tetrahydroisoquinolines

abstract

  • Trabectedin demonstrates superior disease control versus conventional dacarbazine in patients who have advanced liposarcoma and leiomyosarcoma after they experience failure of prior chemotherapy. Because disease control in advanced sarcomas is a clinically relevant end point, this study supports the activity of trabectedin for patients with these malignancies.

publication date

  • March 10, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5070559

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.62.4734

PubMed ID

  • 26371143

Additional Document Info

start page

  • 786

end page

  • 93

volume

  • 34

number

  • 8